广西医学2018，Vol.40Issue(8)：894-897,916,5.DOI:10.11675/j.issn.0253-4304.2018.08.08
贝伐单抗治疗晚期胃癌的疗效及对肠黏膜屏障功能、基质金属蛋白酶2和9的影响
Efficacy of bevacizumab for advanced gastric cancer and its effect on intestinal mucosal barrier function,matrix metalloproteinase 2 and matrix metalloproteinase 9
摘要
Abstract
Objective To investigate the efficacy of bevacizumab as targeted therapy for advanced gastric cancer and its effects on intestinal mucosal barrier function,matrix metalloproteinase(MMP)-2 and MMP-9. Methods A total of 100 patients with advanced gastric cancer were randomly divided into observation group and control group,with 50 cases in each group.The control group was given conventional chemotherapy of cisplatin combined with docetaxel,and the observation group was given targeted therapy using bevacizumab on the basis of the therapy in the control group.The serum levels of MMP-2 and MMP-9,as well as intestinal mucosal barrier function,were compared between the two groups before and after chemotherapy,and the clinical efficacy and incidence of adverse reactions were observed in both groups.Results There were no significant differences in the urinary lactulose to mannitol(L/M) ratio,serum level of MMP-2, MMP-9,D-lactate,procalcitonin or IgA between the two groups before chemotherapy(all P>0.05).After chemotherapy,the serum levels of MMP-2,MMP-9,D-lactate,procalcitonin and IgA were all lower and the urinary L/M ratio was higher in both groups compared to those before chemotherapy,and the improvement of the indexes above in the observation group were more significant than that in the control group(all P<0.05).The rates of thrombocytopenia,liver and kidney dysfunction,bone marrow suppression,leukocytopenia and severe adverse reactions due to diarrhea were lower but the effective rate of treatment was higher in the observation group than those in the control group(all P<0.05).Conclusion For patients with advanced gastric cancer,chemotherapy plus targeted therapy using bevacizumab can effectively reduce serum MMP-2 and MMP-9 levels,improve intestinal mucosal barrier function,decrease severe adverse reactions and enhance clinical efficacy.关键词
晚期胃癌/贝伐单抗/肠黏膜屏障功能/基质金属蛋白酶2/基质金属蛋白酶9Key words
Advanced gastric cancer/Bevacizumab/Intestinal mucosal barrier function/Matrix metalloproteinase 2/Matrix metalloproteinase 9分类
医药卫生引用本文复制引用
国麟祺,陈颖,曲义坤,周晓红,夏伟滨,徐剑,滕欣丽..贝伐单抗治疗晚期胃癌的疗效及对肠黏膜屏障功能、基质金属蛋白酶2和9的影响[J].广西医学,2018,40(8):894-897,916,5.基金项目
佳木斯大学科研项目(S2012-099) （S2012-099）
